View Item 

Evolution and governance of the biotechnology and pharmaceutical industry of China

Access Status
Open access
Authors
Wang, K.
Hong, J.
Marinova, Dora
Zhu, L.
Date
2009
Type
Journal Article

Metadata
Show full item record
Citation
Wang, Kai and Hong, Jin and Marinova, Dora and Zhu, Liang. 2009. Evolution and governance of the biotechnology and pharmaceutical industry of China. Mathematics and Computers in Simulation. 79 (9): pp. 2947-2956.
Source Title
Mathematics and Computers in Simulation
DOI
ISSN
School
Sustainable Policy Institute (CUSP)
Remarks

NOTICE: this is the author’s version of a work that was accepted for publication in Mathematics and Computers in Simulation. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Mathematics and Computers in Simulation, 79, 9, 2009 DOI 10.1016/j.matcom.2008.09.001

URI
Collection
Abstract

The high-speed growth of China’s biotechnology industry during the past 20 years presents an excellent opportunity to examine its overall evaluation and governance from the perspective of science and technology policies. Although China’s biotechnology industry has achieved tremendous extension both in scale and structure, the strengths it has gained from achievements in research and development activities have been significantly weakened in relation to processes of commercialization. After examining the definition of China’s biotechnology industry as well as its evolution, the authors of this paper employ Actor-Networks Theory as a basic theoretical framework to reveal how China’s biotechnology industry develops in the form of evolving networks within the country’s social context and to identify what kinds of relationships exist among the relevant factors. Our hope is to provide guiding insights for improving the governance of China’s biotechnology industry both in policy and in management practices.